DDR Inhibitors Summit 2024

RNA sequencing (RNA-Seq) is critical to developing the next generation of cancer therapies. Data from tumor gene expression is rich in biological information, including cellular composition, the tumor cell type of origin, the tumor microenvironment (TME), drug target overexpression, oncogenic pathway signaling, and prognostic/predictive cell states such as HRD. Because of this richness, it is vital to understand, leverage, and validate RNA at every stage of drug development, including target discovery and selection, molecular characterization across the patient journey, mechanistic studies, predicting and characterizing drug sensitization and resistance, clinical trial design, combined and multimodal therapeutic opportunities, trial recruitment, indication expansion, TME characterization, and CDx development.